← Eichor
Study identifier: NCT06860802 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

Precision Antibiotic Dosing for Appendectomy

Condition: Appendicitis (Diagnosis)  ·  Sponsor: University of Michigan

PhasePhase 1
Planned participants46
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

This research is studying a drug called cefoxitin already approved by the Food and Drug Administration (FDA) to reduce the risk of infection after surgery to remove an appendix. Researchers are studying a large group of people to continue to learn how best to dose antibiotics. This research will compare the current standard treatment which is a single dose prior to surgery to a new method that includes adding another dose of cefoxitin within 30 minutes of starting the surgery. This study will measure cefoxitin concentrations in blood, fat, and appendix tissue samples to compare the standard dosing method to our new method. This information will help us figure out the right dose of this drug to prevent infection after surgery to remove an appendix.

This description comes directly from the study's public registry record.

Talk to the study team

Alexsas Matvekas, BS  ·  7346470006  ·  matvekas@umich.edu

June Sullivan, MBA  ·  734.615-3488  ·  jusulli@med.umich.edu

Always discuss trial participation with your own doctor first.

Locations (1)

Michigan MedicineAnn Arbor, Michigan, United StatesRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06860802